Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging

Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications

“…The results of previous clinical studies with such drugs may now be reinterpreted in the context of the pathophysiology of ceramide signalling. This is illustrated here by findings that the antidepressant drug fluoxetine tends to reduce the formation of new brain lesions in patients with multiple sclerosis [129][130][131]. Fluoxetine works as a FIASMA [91].…”

Microstructural brain abnormalities in medication-free patients with major depressive disorder: a systematic review and meta-analysis of diffusion tensor imaging

“…The inclusion of medicated patients may bias meta-analyses and limit the interpretability and generalizability of the results, as a few studies have reported the effects of antidepressant medication on white matter microstructure. [33][34][35] One study reported that the increment in rich club hub connections was greater in the creatine group than in the placebo group, suggesting the effects of creatine administration on brain network organization may partly underlie its efficacy in treating women with MDD. 36 Moreover, compared with patients who had current MDD, those with remitted MDD showed an altered pattern of intracommunicability within the default mode network (DMN) and intercommunicability between the DMN and other subnetworks, including the visual recognition network and salience network, after treatment with selective serotonin reuptake inhibitors.…”

Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive–compulsive disorder

“…Other limitations include pharmacological treatment and comorbid diagnoses of patients. Most of them were receiving SSRIs at the time of the DTI examination, which could potentially alter diffusivity coefficients (Sijens et al, 2008). In any event, the exact effect of pharmacological treatment or comorbidity on WM microstructure remains an open question but should be taken into consideration when discussing potential causes of data heterogeneity (Koch et al, 2014).…”